⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRME News
Prime Medicine, Inc. Common Stock
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
globenewswire.com
PRME
Form 8-K
sec.gov
PRME
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
globenewswire.com
PRME
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast
globenewswire.com
CRSP
NTLA
EDIT
BEAM
SANG
CELC
CRBU
PRME
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
globenewswire.com
PRME
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
globenewswire.com
PRME
Form 8-K
sec.gov
PRME
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
PRME
Prime Medicine to Present at Jefferies Global Healthcare Conference
globenewswire.com
PRME
Form 8-K
sec.gov
PRME